Skip to content
Careers
Contact us
Our Company
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Investors
Sponsorship
Indications
Overview
Diabetic Nephropathy
Non-alcoholic steatohepatitis
Type 1 Diabetes
Progressive Fibrosing – Interstitial Lung Disease
Prader-Willi Syndrome
Our Approach
Peripheral CB1 Blockade
The Endocannabinoid System
CB1 Inverse Agonists
References
Our Pipeline
Peripherally-acting CB1 Inverse Agonists
Pipeline Development Pathways
About INV-202 and INV-101
News & Events
FR
EN
Menu
Home
Our Company
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Investors
Sponsorship
Indications
Overview
Diabetic Nephropathy
Non-alcoholic steatohepatitis
Type 1 Diabetes
Progressive Fibrosing – Interstitial Lung Disease
Prader-Willi Syndrome
Our Approach
Peripheral CB1 Blockade
The Endocannabinoid System
CB1 Inverse Agonists
References
Our Pipeline
Peripherally-acting CB1 Inverse Agonists
Pipeline Development Pathways
About INV-202 and INV-101
News & Events
Careers
Media
Contact us
Contact us
Contact us
Contact us
Please take note of our new address as of January 4, 2022
1100 René-Lévesque Blvd West
Suite 1110
Montreal, Quebec
H3B 4N4 Canada
1 438 300-2534
Loading…
